A Canadian Psychedelic Survey (CPS), co-sponsored by SABI Mind, MAPS PBC and Psygen Industries, recently shared the results of a survey on the characteristics, patterns of use and access to psychedelic drugs.

Designed in collaboration with clinicians and academic researchers from renowned universities, the 655-question poll seeks to gather real-world evidence on psychedelics use in Canada.

The CPS focused on the use of 11 psychedelics: ayahuasca, DMT or 5-MeO-DMT, iboga or ibogaine, LSD or acid, MDMA or MDA, mescaline, psilocybin, and salvia divinorum. 

Additional data was gathered on users and patterns of personal and therapeutic use, as well as the relationship between psychedelics and headaches/migraines, mental health, music, mindfulness practices, and the use of alcohol, tobacco and other drugs.

Participants reported a range of access sources under the country’s current legal framework and an interest in obtaining psychedelic drugs through more formal regulated channels. 

Data collected anonymously from 2045 respondents over 19 with a mean age of 38 and 56% of them female, showed: 

Full story available on Benzinga.com

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.